Data From Incyte’s Oncology Portfolio to Be Presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
November 07 2022 - 8:00AM
Business Wire
Incyte (Nasdaq:INCY) today announced that abstracts featuring
data from its oncology portfolio will be presented at the upcoming
Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting,
held November 8-12, 2022, in Boston and virtually.
“We are proud of the progress being made across our
earlier-stage clinical programs, spanning small molecules,
monoclonal and bispecific antibodies,” said Lance Leopold, M.D.,
Group Vice President, Clinical Development Hematology and Oncology
at Incyte. “We look forward to presenting data at the SITC Annual
Meeting from our immuno-oncology pipeline, including our oral PD-L1
program, as we make progress toward our goal of identifying new
solutions for patients with cancer who need additional
options.”
Key abstracts include:
Poster Presentations
All accepted odd-numbered posters are available from 9:00
a.m. – 9:00 p.m. EST on Thursday, November 10. All accepted
even-numbered posters are available Friday, November 11, from 9:00
a.m.–8:30 p.m. EST.
INCB099280 (PD-L1)
A Phase 1 Study Exploring the Safety and Tolerability of the
PD-L1 Small Molecule Inhibitor INCB099280 in Patients with Select
Advanced Solid Tumors (Abstract #734)
INCB099318 (PD-L1)
A Phase 1 Study Exploring the Safety and Tolerability of the
Small Molecule PD-L1 Inhibitor, INCB099318, in Patients with Select
Advanced Solid Tumors (Abstract #662)
INCB086550 (PD-L1)
A Phase 1 Study Exploring the Safety and Tolerability of the
Small Molecule PD-L1 Inhibitor, INCB086550, in Patients with Select
Advanced Tumors (Abstract #774)
INCA32459 (LAG3xPD-1)
Phase 1 First-in-Human, Open-Label, Multicenter Study of
INCA32459, a Bispecific Anti–PD1 and Anti–LAG-3 Antibody, in
Patients with Select Advanced Malignancies (Abstract #723)
A Human Bispecific Antibody Targeting LAG-3 and PD-1 (INCA32459)
Potently Activates Exhausted T Cells (Abstract #1210)
INCAGN01876 (GITR)
A Phase 2, Open-Label, Multicenter Study of INCAGN01876
(anti-GITR agonist) in Combination with Retifanlimab (anti–PD-1) in
Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
(Abstract #677)
Bispecific Antibody Research
Comparison of Four in Vitro Cytotoxicity Assays for Assessing
the Potency of Bispecific Antibodies Redirecting T Cells to Kill
Tumor Target Cells (Abstract #1199)
More information regarding the congress is available on the SITC
website: https://www.sitcancer.org/2022/home. The virtual meeting
platform will be available following the conclusion of the meeting
for registered attendees until Monday, Jan. 9, 2023.
About Incyte Incyte is a Wilmington, Delaware-based,
global biopharmaceutical company focused on finding solutions for
serious unmet medical needs through the discovery, development and
commercialization of proprietary therapeutics. For additional
information on Incyte, please visit Incyte.com and follow
@Incyte.
Forward-Looking Statements Except for the historical
information set forth herein, the matters set forth in this press
release, including statements regarding the presentation of data
from Incyte’s clinical development pipeline, whether or when any
development compounds or combinations will be approved or
commercially available for use in humans anywhere in the world
outside of the already approved indications in specific regions and
Incyte’s goal of improving the lives of patients, contain
predictions, estimates and other forward-looking statements.
These forward-looking statements are based on Incyte’s current
expectations and subject to risks and uncertainties that may cause
actual results to differ materially, including unanticipated
developments in and risks related to: unanticipated delays; further
research and development and the results of clinical trials
possibly being unsuccessful or insufficient to meet applicable
regulatory standards or warrant continued development; the ability
to enroll sufficient numbers of subjects in clinical trials; the
effects of the COVID-19 pandemic and measures to address the
pandemic on Incyte and its partners’ clinical trials, supply chain,
other third-party providers and development and discovery
operations; determinations made by the U.S. FDA and other
regulatory authorities outside of the United States; the efficacy
or safety of Incyte and its partners’ products; the acceptance of
Incyte and its partners’ products in the marketplace; market
competition; sales, marketing, manufacturing and distribution
requirements; and other risks detailed from time to time in
Incyte’s reports filed with the Securities and Exchange Commission,
including its annual report and its quarterly report on Form 10-Q
for the quarter ended September 30, 2022. Incyte disclaims any
intent or obligation to update these forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221107005169/en/
Media Catalina Loveman +1 302 498 6171
cloveman@incyte.com
Investors Christine Chiou +1 302 274 4773
cchiou@incyte.com
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Jul 2023 to Jul 2024